Search

Displaying results 5251 - 5260 of 5277 in total
  1. Drug

    GI-181771X

    go.drugbank.com/drugs/DB12309
    Experimental

    Gski181771 X is under investigation in clinical trial NCT00600743 (Effect of a CCK-1R Agonist on Food Intake in Humans).

  2. Drug

    Ioglicic acid

    go.drugbank.com/drugs/DB13701
    Experimental

    Categories: X-Ray Contrast Media, Iodinated, Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast Media
  3. Drug

    Malic acid

    go.drugbank.com/drugs/DB12751
    Investigational

    Malic acid has been used in trials studying the treatment of Xerostomia, Depression, and Hypertension.

    Mixtures: AMINOPLASMAL-5% E INFUSION, AMINOPLASMAL-10% E INFUSION
  4. Drug

    Trifarotene

    go.drugbank.com/drugs/DB12808
    ApprovedInvestigational

    Trifarotene is a topical retinoid cream used in the treatment of acne vulgaris that was first approved for use in the United States in October 2019. Retinoids are a class of medications structurally and functionally analogous to vitamin ...

  5. Drug

    Oprelvekin

    go.drugbank.com/drugs/DB00038
    ApprovedInvestigationalWithdrawn

    Oprelvekin, the active ingredient in Neumega®, is recombinant Interleukin-11 (IL-11), which is produced in Escherichia coli (E. coli) by recombinant DNA technology.

  6. Drug

    Tamibarotene

    go.drugbank.com/drugs/DB04942
    Investigational

    Tamibarotene is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.

  7. Drug

    E-2012

    go.drugbank.com/drugs/DB05171
    Experimental

    E-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.

  8. Drug

    CEQ508

    go.drugbank.com/drugs/DB17911
    Experimental

    CEQ508 is a Live Attenuated E. Coli Expressing Beta Catenin ShRNA currently being investigated to treat Familial Adenomatous Polyposis.

  9. Drug

    GMI-1359

    go.drugbank.com/drugs/DB18092
    Investigational

    GMI-1359 is a small molecule, glycomimetic compound with dual inhibitory activity against E-selectin and CXCR4.[A261406]

  10. Drug

    PF-05230907

    go.drugbank.com/drugs/DB18417
    Investigational

    PF-05230907 is a recombinant activated Factor X variant.